An expanded role for clinical coordinators in investigator initiated clinical trial research

....................................................................................................................... ii ACKNOWLEDGEMENTS ............................................................................................... iv LIST OF FIGURES ............................................................................................................ x INTRODUCTION .............................................................................................................. 1 RESEARCH QUESTION AND APPROACH ................................................................... 5 LITERATURE REVIEW ................................................................................................... 8 3.1 Postoperative Adhesions ........................................................................................ 8 3.2 Pathophysiology of Adhesions .............................................................................. 9 3.3 Complications of Postoperative Adhesions ......................................................... 11 3.3.1 Small Bowel Obstruction .............................................................................. 11 3.3.2 Chronic Pelvic Pain ....................................................................................... 11 3.3.3 Female Infertility ........................................................................................... 13 3.4 Postoperative Adhesion Prevention ..................................................................... 15 3.4.1 Surgical Techniques ...................................................................................... 16 3.4.2 Current Therapies .......................................................................................... 17 3.5 Myomectomy ....................................................................................................... 21 3.5.1 Uterine Fibroids ............................................................................................. 21 3.5.2 Myomectomy and Adhesions ........................................................................ 21 3.5.3 Clinical Research ........................................................................................... 22 3.6 Conclusion ........................................................................................................... 23

[1]  B. Mayer,et al.  Alanyl-glutamine dipeptide restores the cytoprotective stress proteome of mesothelial cells exposed to peritoneal dialysis fluids. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  J. Paratz,et al.  Effect of intravenous GLutamine supplementation IN Trauma patients receiving enteral nutrition study protocol (GLINT Study): a prospective, blinded, randomised, placebo-controlled clinical trial , 2011, BMJ Open.

[3]  Á. Robles,et al.  The effect of l-alanyl-l-glutamine dipeptide supplemented total parenteral nutrition on infectious morbidity and insulin sensitivity in critically ill patients* , 2011, Critical care medicine.

[4]  J. Ruysschaert,et al.  Cationic liposomal lipids: from gene carriers to cell signaling. , 2008, Progress in lipid research.

[5]  R. Durward,et al.  Safety studies of l-alanyl-l-glutamine (l-AG). , 2008, Regulatory toxicology and pharmacology : RTP.

[6]  Takeshi Kimura,et al.  Thirteen-Week Oral Toxicity Study of l-Glutamine in Rats , 2004, International journal of toxicology.

[7]  C. Fuentes-Orozco,et al.  L-alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis. , 2004, Clinical nutrition.

[8]  P. Calder,et al.  Glutamine and the immune system , 1999, Amino Acids.

[9]  Y. Liu,et al.  The impact of alanyl-glutamine on clinical safety, nitrogen balance, intestinal permeability, and clinical outcome in postoperative patients: a randomized, double-blind, controlled study of 120 patients. , 1999, JPEN. Journal of parenteral and enteral nutrition.

[10]  A. Miller.  Therapeutic considerations of L-glutamine: a review of the literature. , 1999, Alternative medicine review : a journal of clinical therapeutic.

[11]  M. Brennan,et al.  L-glutamine supplementation in home total parenteral nutrition patients: stability, safety, and effects on intestinal absorption. , 1994, JPEN. Journal of parenteral and enteral nutrition.

[12]  T. Ziegler,et al.  Safety of glutamine-enriched parenteral nutrient solutions in humans. , 1990, The American journal of clinical nutrition.

[13]  T. Ziegler,et al.  Safety and metabolic effects of L-glutamine administration in humans. , 1990, JPEN. Journal of parenteral and enteral nutrition.

[14]  P. Stehle,et al.  In vivo utilization of intravenously supplied L-alanyl-L-glutamine in various tissues of the rat. , 1989, Nutrition.

[15]  P. Stehle,et al.  Availability of glutamine supplied intravenously as alanylglutamine. , 1989, Metabolism: clinical and experimental.

[16]  S. Adibi.  Intravenous use of glutamine in peptide form: clinical applications of old and new observations. , 1989, Metabolism: clinical and experimental.

[17]  N. Abumrad,et al.  Possible sources of glutamine for parenteral nutrition: impact on glutamine metabolism. , 1989, The American journal of physiology.

[18]  P. Stehle,et al.  Availability of amino acids supplied by constant intravenous infusion of synthetic dipeptides in healthy man. , 1989, Clinical science.

[19]  P. Stehle,et al.  Availability of amino acids supplied intravenously in healthy man as synthetic dipeptides: kinetic evaluation of L-alanyl-L-glutamine and glycyl-L-tyrosine. , 1988, Clinical science.

[20]  S. Adibi,et al.  Influence of molecular structure on half-life and hydrolysis of dipeptides in plasma: importance of glycine as N-terminal amino acid residue. , 1986, Metabolism: clinical and experimental.

[21]  H. G. Windmueller,et al.  Respiratory fuels and nitrogen metabolism in vivo in small intestine of fed rats. Quantitative importance of glutamine, glutamate, and aspartate. , 1980, The Journal of biological chemistry.

[22]  J. Daly.  L-alanyl-L-glutamine dipeptide–supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: The French controlled, randomized, double-blind, multicenter study , 2008 .

[23]  J. Olney,et al.  Cytotoxic effects of acidic and sulphur containing amino acids on the infant mouse central nervous system , 2004, Experimental Brain Research.